A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Primary mediastinal B-cell lymphoma starts in ... lymphoma affects the brain and spinal cord. Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) are a group of cancers that don ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Circulating tumor DNA (ctDNA) has emerged as a valuable tool in revealing molecular heterogeneity and risk factors of large B-cell lymphoma (LBCL ... as diffuse LBCL with a primary mediastinal B-cell ...

B-cell cancers, including CLL and SLL, are a group of malignancies affecting lymphocytes, a type of white blood cell crucial to immune function. These cancers impact thousands, with CLL being the most ...

TORONTO - The economic uncertainty created by U.S. President Donald Trump’s tariffs permeated Ontario’s throne speech Tuesday, a ceremonial offering intended to set the new provincial ...

Roche is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. As part of Roche’s efforts ...

diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT). With this approval, this Columvi combination is the first bispecific ...